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Recent studies indicate that the gag gene products may play a crucial role in the immune response against HIV infection since clinical progression 
to AIDS is associated with a reduction in the level of circulating antibodies to gag p24 and antibodies raised against pl7 peptide can inhibit HIV1 
infection in vitro. Using conventional structure prediction algorithms for T-cell and B-cell epitopes, we have selected and chemically synthesized 
several gag peptides. In particular, an unconjugated HIVI-p24 peptide containing both B- and T-cell epitopes in tandem plus Freund’s adjuvant 
induced a strong antibody response in both mice and rabbits against p24 and its precursor p55 as judged by immunoblotting. In addition, the 
peptide presented in the appropriate MHC context was shown to be highly stimulatory for p24 specific murine T-cell clones. 
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INTRODUCTION 
Recent studies have indicated that the gag gene 
products may play a crucial role in eliciting an immune 
response against HIV infection. The clinical progres- 
sion of AIDS is associated with a reduction in cir- 
culatory antibodies to the gag p24 protein, and an- 
tibodies raised against a p17 peptide are capable of in- 
hibiting HIV-l in vitro [ 1,2]. Since the T-helper deter- 
minant (THD) of Hepatitis B (HB) core protein 
enhances anti-HB S antigen responses [3] we undertook 
to identify and study the possible gag-THD in HIV. Us- 
ing conventional structure prediction algorithms for T- 
cell and B-cell epitopes [4-71, several gag peptide vac- 
cine candidates were selected and synthesized (Table I). 
This paper demonstrates that an unconjugated HIVl- 
p24 peptide (GPKEPFRDYVDRFYKTLRAEQAS- 
QEV), containing both predicted B- and T-cell epitopes 
in tandem is capable of inducing a strong antibody 
response in mice against p24 and its precursor ~55. In 
addition, the peptide presented in the appropriate MHC 
context was shown to be highly stimulatory for p24- 
specific T-cell clones. 
2. MATERIALS AND METHODS 
2.1. Peptides synthesis and purification 
Peptides were chemically synthesized using an Applied Biosystem 
430-A Peptide Synthesizer, and cleaved from resin by HF. Peptides 
were purified by reverse-phase HPLC and their amino acid analyses 
were in good agreement with the theoretical compositions. 
Correspondence address: P. Chong, Connaught Centre for 
Biotechnology Research, Connaught Laboratories Ltd., 1755 Steeles 
Ave. W., Willowdale, Ont., Canada M2R 3T4 
2.2. Immunogenicity of tandem T-B cell epitopes 
The immunogenicity of individual synthetic peptides (50 fig) was 
tested by immunizing Balb/c (Hzd) mice (Charles River) and rabbits 
(Maple Lane Farm, Ont., Canada) with peptides emulsified in com- 
plete Freund’s adjuvant, followed by a booster injection 2-3 weeks 
later with the same peptides emulsified in incomplete Freund’s adju- 
vant. Antisera raised against these peptides were collected 2 weeks 
after the last challenge and tested for their reactivity against HIV1 an- 
tigens by ELISA and immunoblotting. 
2.3. Assay for synthetic T-cell epitopes 
The immunogenicities of synthetic peptides were assessed by their 
ability to stimulate the proliferation of a long-term L3T4+ T-cell line 
(HIV-l p24/10) specific for a synthetic 104-mer peptide corre- 
sponding to the C-terminal half of p24 [8]. 
2.4. ELZSA 
Reactivities of the peptide-specific murine antisera gainst recombi- 
nant core proteins and antigens of HIV-1 were determined by using 
test kits purchased from Abbott Laboratories (IL, USA). Procedures 
for performing these tests were followed as described by the manufac- 
turer, except for the following modifications. The polystyrene beads 
coated with recombinant material or anti-HIV antibody were treated 
with phosphate-buffered saline (pH 7.2) containing 5% (v/v) normal 
mouse serum for 2 h at room temperature before being used for the 
tests. In addition, a sheep anti-mouse IgG peroxidase conjugate (ab- 
sorbed with human serum proteins, Sigma Chemical Co.) was used to 
detect the binding of specific mouse IgG antibodies to the recombi- 
nant core proteins or antigens of HIV-l. 
2.5. Immunoblots 
Antibodies raised in mice and rabbits against he synthetic peptides 
were tested for their immunospecificity using the immunoblot tech- 
nique. HIV-1 viral proteins on strips were purchased from Bio-Rad 
and immunoblots were performed according to the manufacturer’s 
specification. Anti-peptide sera were diluted 1: 100 and I :500 for mice 
and rabbit sera, respectively. Protein A alkaline phosphatase con- 
jugate (Bio-Rad) was used as the reporting group. The substrate 
NBT:BCIP (Bio-Rad) was used for color development. 
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Table I 
Immunogenicity of the predicted T-B cell epitopes in the gag gene products of 
HIV-l 
Antibody responsea 
Peptides Sequenceb Mice Rabbits 
P17A EELRSLYNTVAT _ - 
P17B DTKEALDKIEEEQNKSKKKA - N.D. 
P24A RTLNAWVKVVEEKAFSPEVIP - +++ 
P24B LKETINEEAAEWDRVHPVHAG - +++ 
P24C GQLREPRGSDIAGTTSTLQEQI - - 
P24D IPVGEIYKRWIILGLNKIVRMYSP - ++ 
P24E GPKEPFRDYVDRFYK - - 
HIVl-p24 GPKEPFRDYVDRFYKTLRAEQASQEV +++ +++ 
P24F LEEMMTACQGVGGPGHKARVLAEA + + - 
P24G TETLLVQNANPDCKTILKALGPAA ++ + 
P15A ARNCRAPPKKGCWKCGKEGHQMKDC - N.D.’ 
a Antibody responses were assayed by immunoblot analysis. The negative sign 
represents antisera that do not recognize p24 and its precursor ~55 in im- 
munoblots; the positive sign indicates that the antisera recognize p24 and ~55. 
The + , + + , + + + represent he dilution of the sera: 1: 100, 1: 500, and 
1 : 2000, respectively 
b Peptide sequences are based on the LAV isolate sequence reported by Alison 
et al. [15].- 
’ N.D., not determined 
3. RESULTS AND DISCUSSION 
Several examples (diphtheria, tetanus and HB) have 
shown that protective antibodies against a specific 
disease can be elicited by the administration of specific 
components of the pathogen [9]. The envelope protein 
(gp160) of HIV-l has been tested as a candidate recom- 
binant or vaccinia expressed vaccine against HIV, and 
although it can induce virus-specific antibodies, it has 
failed to protect primates against challenge with wild- 
type HIV isolates. In addition, two regions of the pro- 
tein gp160, residues 735-752 and 846-860, have been 
shown to suppress the normal lymphocyte proliferative 
response to mitogens [lo]. Peptide-mediated immuno- 
suppression may play an important role in the patho- 
genesis of the disease [11,12]. These results stress the 
need of a rational design for a synthetic vaccine against 
AIDS. To design the best candidate vaccine, strong 
viral B-cell neutralizing epitopes (BE) containing a high 
degree of conserved sequence between viral isolates 
must be linked to potent T-helper determinants (THD) 
to yield an intense and long-lasting cross-protective an- 
tibody response. It is, therefore, important to locate the 
most potent THD of the various HIV antigens, encoded 
by the env, gag, and pol genes. The number of linear 
THD and BE of the gp160 protein have been 
characterized [13]. Although the B- and T-epitopes of 
gag and pol proteins have been predicted by standard 
algorithms [14], these epitopes have yet to be determin- 
ed experimentally. 
Using conventional structure prediction algorithms 
for T-cell and B-cell epitopes [4-71, several gag peptides 
have been synthesized and purified by RP-HPLC 
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(Table I). To assess the immunogenicity of the gag- pep- 
tides, rabbits and inbred Balb/c mice were injected with 
individual peptides (SO- 100 pg) emulsified in complete 
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Fig. 1. Immunoblot of anti-HIVl-p24 antisera. Nitrocellulose im- 
muno-strips of HIV-l gene products (Bio-Rad) were reacted with 
murine and rabbit anti-HIVl-p24 antisera. A: lane 1, pooled sera 
from unprimed Balb/c mice; lane 2, pooled antisera from immunized 
Balb/c mice; lane 3, pooled antisera from C57BL/6 mice; lane 4, 
pooled antisera from C3H mice. B: lane 1, rabbit preimmune serum; 
lane 2, antiserum from a rabbit primed and boosted with HIVl-p24 
peptide. 
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Fig. 2. Reactivities of HIVl-p2Cspecific Balb/c mice antisera against 
recombinant p24 as determined by ELISA. 
Freund’s adjuvant. After a booster dose with the same 
immunogen in incomplete Freund’s adjuvant, sera were 
collected and tested for peptide-specific and gag- 
specific antibodies in immunoblots, The data sum- 
marized in Table I, indicate that not all gag peptides 
were capable of inducing a strong antibody response 
against p24 and its precursor ~55 both in mice and rab- 
bits, as judged by immunoblot analysis. In fact, peptide 
HIVl-p24 is the only one which consistently induced a 
strong antibody response against p24 in these animals 
(Fig.lA,B). These results confirm that peptide HJVI- 
p24 contains both B- and T-cell epitopes in tandem. 
Therefore, all further work has been concentrated on 
HIVl-~24. 
In order to assess the potency of HIVl-~24, mice 
were immunized with increasing amounts of peptide, 
emulsified in incomplete Freund’s adjuvant (2 to 50 pg). 
Mouse antisera generated with all three doses recogniz- 
ed gag-p24 and its precursor in immunoblot analysis 
(data not shown). The reactivity of mouse anti-HIVI- 
p24 antisera against gag-p24 was evaluated by ELISA. 
As shown in Fig. 2, all three antisera reacted well with 
recombinant p24 in a dose-dependent fashion. The im- 
munogenicity of the synthetic peptide HIVl-p24 was 
further assessed by its ability to stimulate the prolifera- 
tion of a long-term L3T4+ T-cell line (HIVl-~24110) 
specific for a synthetic 1OCmer peptide corresponding 
to the C-terminal half of p24 [S]. The results summariz- 
ed in Table II, showed that HIVl-p24 was capable of 
inducing a strong proliferative response in this T-cell 
line. 
To determine whether the synthetic peptide HIVI- 
p24 could induce an immune response in other strains 
of mice, both C3H (H2k) and C57BL/6 (H2b) strains of 
mice were immunized with 50 pg peptide emulsified 
in complete Freund’s adjuvant, then boosted with the 
same amount of immunogen in incomplete Freund’s 
adjuvant. Antisera from both strains of mice were 
tested against HIV1 viral proteins, and showed to be 
able to recognize p24 and its precursor ~55 in the im- 
munoblot analysis (Fig.lA, lanes 3 and 4). These data 
strongly suggest that HIVI-p24 can be efficiently 
prevented by several MHC class II haplotypes. 
To identify which residues in HIVI-p24 were critical 
for inducing an antibody response, a truncated peptide 
P24E was prepared and tested. Antisera from Balb/c 
mice and rabbits immunized with P24E failed to 
recognize p24 in both ELISA and immunoblot anal- 
yses. Although P24E failed to induce antibodies against 
gag-p24, it retained the ability to stimulate the pro- 
liferation of both the-p24-specific murine T-cell line 
(Table II) and T-lymphoc~es from AIDS patients ]16]. 
These results suggest hat (i) the functional T-helper cell 
epitope of peptide HIVl-p24 is located within the 16 N- 
terminal residues; and (ii) the C-terminal sequences 
Table II 
Proliferative response of the HIVl-p24 specific murine T-cell line HIV-l 
p24/10 to synthetic p24 peptides* 
Peptide (sH)-TdR uptake (cpm) 
concentration 
&g/ml) 
HIVl-p24 P24E BE3’ TAT’ 104-merd 
10 2034b 1663 189 325 2550 
2 1264 3265 176 253 1317 
0.4 522 1031 132 182 756 
0.08 401 N.D.’ 130 146 831 
a Murine lymphoblasts were harvested from spleen cells stimulated with the p24 
104-mer peptide [8] and subsequently cultured in IL-2 containing medium for 
7 days before stimulation with the synthetic peptides presented by irradiated 
(1700 R) autologous spleen cells used as antigen-presenting cells. 
b Results are expressed as mean counts per min (cpm) of triplicate cultures. All 
SDS were less than 15%. 
’ BE3 and TAT served as negative control peptides. BE3 and TAT are synthetic 
peptides from gpl60 (residues 726-750) and Tat (l-87) gene products of 
HIV-l, respectively. 
d p24 104-mer corresponds to the C-terminal half of the gag p24 gene product 
and was prepared as prevjously described [8]. 
’ N.D., not determined. 
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(TLRAEQASQEV) are essential for inducing an an- 
tibody response. 
4. CONCLUSION 
We have identified and synthesized atandem T-B-cell 
epitope of HIVl-~24. This synthetic peptide was found 
to be a very potent immunogen which induced both a T- 
cell proliferative response and anti-p24 an antibody 
response in both rabbits and mice. The anti-peptide an- 
tibodies reacted with recombinant p24 in ELISA and 
with the mature core protein and its ~55 precursor on 
immunoblotting. This tandem peptide should serve as a 
model for the rational design of a fully s~thetic HIV-l 
vaccine. 
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